# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...
EF Hutton analyst Tim Moore maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and raises the price target from $6.5 to $7.
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...
Hoth Therapeutics reveals preclinical findings on HT-ALZ, a potential Alzheimer's therapeutic targeting the Substance P/Neu...
CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; S...
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer...